Grogan Jane 4

What Happened

• Jane Grogan, Head of Research at Biogen (BIIB), received a grant of 8,450 restricted stock units (RSUs) on February 13, 2026. The filing records the acquisition price as $0.00, indicating a non-cash equity award rather than a market purchase.

Key Details

• Transaction date: 2026-02-13; Form 4 filed: 2026-02-17 (filed within the standard 2 business-day window).
• Award: 8,450 RSUs; acquisition price reported as $0.00 (derivative equity award).
• Shares owned after the transaction: not disclosed in the Form 4 filing.
• Footnote: The RSUs vest in three equal yearly installments beginning on the first anniversary of the grant date (Feb 13, 2027) — final vesting over three years.
• Transaction type: A = Award/Grant (derivative securities).

Context

• RSUs are compensation grants that convert to actual shares only as they vest; they do not represent an immediate cash purchase or sale. Such awards are common for executives and typically reflect compensation/retention, not a straightforward buy/sell signal about market sentiment.